Straits Times Index
3,301.42 +8.49 (+0.26%) Nikkei
38,236.07 -38.03 (-0.10%) Hang Seng
18,466.91 -9.01 (-0.05%) FTSE 100
8,213.49 +41.34 (+0.51%) Bitcoin USD
64,023.02 +701.34 (+1.11%) CMC Crypto 200
1,328.11 +51.13 (+4.00%)
AZN Jan 2025 77.500 put
- Zacks
Top Analyst Reports for AstraZeneca, QUALCOMM & FedEx
Today's Research Daily features new research reports on 16 major stocks, including AstraZeneca PLC (AZN), QUALCOMM Incorporated (QCOM) and FedEx Corporation (FDX).
- Zacks
Amgen (AMGN) Q1 Earnings Top, Stock Up on Obesity Drug Update
Amgen (AMGN) beats first-quarter 2024 estimates for earnings and sales. Amgen is "very encouraged" by interim data from the phase II study on obesity candidate MariTide.
- Business Wire
CALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial
WILMINGTON, Del., May 02, 2024--Positive high-level results from an interim analysis of the ECHO Phase III trial showed AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with standard-of-care chemoimmunotherapy, bendamustine and rituximab, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus standard of care in previously untreated adult patients with mantle cell lymphoma (MCL).
